

Instructions for Use

# CellGenix<sup>®</sup> GMP TCM

Protocol for Lentiviral Transduction and Expansion of CD3<sup>+</sup> T Cells In  
CellGenix<sup>®</sup> GMP TCM

SARTORIUS



# Contents

<b>1</b>	<b>Safety</b> .....	<b>4</b>
1.1	Intended Use.....	4
<b>2</b>	<b>Media Preparation</b> .....	<b>4</b>
<b>3</b>	<b>Cell Preparation</b> .....	<b>4</b>
3.1	Fresh Cells .....	4
3.2	Frozen Cells.....	5
<b>4</b>	<b>Cell Activation and Seeding</b> .....	<b>5</b>
<b>5</b>	<b>Transduction: Day 1</b> .....	<b>6</b>
<b>6</b>	<b>Expansion: Day 3 – 6 – 8 – 10</b> .....	<b>6</b>
<b>7</b>	<b>Cell harvest: Day 10</b> .....	<b>7</b>
<b>8</b>	<b>Additional Information</b> .....	<b>7</b>

# 1 Safety

## 1.1 Intended Use

For research and further manufacturing use only.

# 2 Media Preparation

1. For a 10-day cultivation in 96 well plate, 4 mL of CellGenix® GMP TCM is needed per donor.
2. Supplement CellGenix® GMP TCM with CellGenix® IL-7 (10 ng/mL) and CellGenix® IL-15 (10 ng/mL). Antibiotics may be added as necessary e.g., Penicillin | Streptomycin 100 U/mL.
3. Prepare fresh media with cytokines on each day of cultivation.

# 3 Cell Preparation

## 3.1 Fresh Cells

1. Prepare fresh CD3<sup>+</sup> T cells from apheresis or buffy coat using negative isolation, e.g. by EasySep™ Human T Cell Isolation Kit, Stemcell Technologies.
2. Wash cells in PBS to remove remaining EDTA from purification buffer.
3. Spin cells down at 300xg, 21°C for 10 minutes. Carefully aspirate supernatant.
4. Resuspend cells in an appropriate volume of supplemented CellGenix® GMP TCM to a target density of  $1 \times 10^7$  cells/mL. Cell suspension will be used for cell activation.

Optional: 45 µm cell strainer may be applied to obtain a highly pure single cell solution.

## 3.2 Frozen Cells

1. Prepare 10 mL pre-warmed CellGenix® GMP TCM in a 15 mL conical tube.
2. Thaw one vial of purified CD3<sup>+</sup> T cells by gently swirling the vial in the 37°C water bath until there is just a small clump of ice left in the vial.
3. As soon as cells are thawed, quickly transfer cells to the prewarmed CellGenix® GMP TCM and invert the tube 3 times.
4. Spin cells down at 300xg, 21°C for 10 minutes. Carefully aspirate supernatant.
5. Resuspend cells in an appropriate volume of supplemented CellGenix® GMP TCM to a target density of  $1 \times 10^7$  cells/mL. Cell suspension will be used for cell activation.

Optional: 45 µm cell strainer may be applied to obtain a highly pure single cell solution.

## 4 Cell Activation and Seeding

---

### NOTE

This protocol is designed to cultivate 3 wells for each medium and donor. If more replicates are required, the volumes have to be adjusted.

---

1. Prepare anti- CD3<sup>+</sup> and anti-CD28 cell activation beads e.g. Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher) for a target ratio of 1:1 bead:cells. Mix 9.75 µL beads with 350 µL supplemented CellGenix® GMP TCM to achieve a target ratio of beads:cells of 1:1 for  $3.5 \times 10^5$  CD3<sup>+</sup> T cells.
2. Mix 315 µL of the bead | medium solution with 35 µL of the CD3<sup>+</sup> T cell suspension by pipetting up and down 3 times in a 1.5 mL reaction tube.
3. Transfer 100 µL of the CD3<sup>+</sup> T cells | activation bead suspension in 3 wells of a 96 well plate (flat bottom). This results in a seeding density of  $1 \times 10^6$  CD3<sup>+</sup> T cells/mL.
4. Add 200 µL sterile PBS buffer in the surrounding wells to avoid media evaporation.
5. Incubate cells overnight in a humidified incubator at 5% CO<sub>2</sub> at 37°C.

## 5 Transduction: Day 1

### NOTE

Viral safety precautions need to be followed.

1. Prepare pre-warmed CellGenix® GMP TCM supplemented with CellGenix® IL-7 (10 ng/mL) and CellGenix® IL-15 (10 ng/mL).
2. Add lentiviral particles to achieve the desired multiplicity of infection (MOI). For an MOI of 3 prepare  $1.5 \times 10^6$  lentiviral particles in 0.5 mL medium. The added virus preparation should have a concentration of  $> 6 \times 10^7$  transduction units/mL to avoid strong T cell media dilution.
3. Gently add 100  $\mu$ L of medium containing the viral particle to each well with activated CD3<sup>+</sup> T cells. The final cultivation volume is now 200  $\mu$ L.
4. Incubate cells in a humidified incubator at 5% CO<sub>2</sub> at 37°C.

## 6 Expansion: Day 3 – 6 – 8 – 10

1. On each splitting day prepare CellGenix® GMP TCM supplemented with CellGenix® IL-7 (10 ng/mL) and CellGenix® IL-15 (10 ng/mL).
2. Transfer an appropriate volume of medium to a new 96 well plate. The volumes of medium and cell suspension for the splits are listed in table on the right.
3. Pre-warm the plate to 37°C.
4. After thorough resuspension of the T cells transfer, the appropriate volume to the new 96 well plate.
5. Incubate cells in a humidified incubator at 5% CO<sub>2</sub> at 37°C.

Day	Ratio	Volume Medium	Volume Cells
3	1:8	175 $\mu$ L	25 $\mu$ L
6	1:4	150 $\mu$ L	50 $\mu$ L
8	1:2	100 $\mu$ L	100 $\mu$ L

## 7 Cell harvest: Day 10

1. Determine cell number, viability and transduction efficiency.

## 8 Additional Information

- It's important for your cultivation process to investigate the optimal seeding density for your cultivation process and system.
- The MOI directly influences your transduction efficiency as well as your process costs. Thus, the amount of lentivirus for your process should be tested in various concentrations to reach the expected results.
- From day 3 on carefully observe the density of the cells under the microscope as high densities ( $> 1.5 \times 10^6$  cells/mL), can result in undesired phenotypes or exhaustion. Split ratios can be adjusted accordingly.
- This 96 well plate assay is designed for media screening. If lentiviral transduction is not required increase the total seeding volume on day 0 to 200  $\mu$ L, omit viral transduction on day 1 and follow the protocol as described.

Sartorius Stedim Biotech GmbH  
August-Spindler-Strasse 11  
37079 Goettingen, Germany

Phone: +49 551 308 0  
[www.sartorius.com](http://www.sartorius.com)

The information and figures contained in these instructions correspond to the version date specified below.

Sartorius reserves the right to make changes to the technology, features, specifications and design of the equipment without notice.

Masculine or feminine forms are used to facilitate legibility in these instructions and always simultaneously denote all genders.

Copyright notice:

These instructions, including all components, are protected by copyright.

Any use beyond the limits of the copyright law is not permitted without our approval.

This applies in particular to reprinting, translation and editing irrespective of the type of media used.

Last updated:

05 | 2023

© 2023  
Sartorius CellGenix GmbH  
Am Flughafen 16  
79108 Freiburg, Germany

LM | Publication No.: SCM6021-e230501